Literature DB >> 2230260

Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.

R B Jones1, B Van der Pol, D H Martin, M K Shepard.   

Abstract

In vitro susceptibility testing was done on urogenital isolates of Chlamydia trachomatis from five patients, four of whom were suspected treatment failures. At least one isolate from each patient was resistant to tetracycline at concentrations greater than or equal to micrograms/ml, although less than 1% of a population of organisms showed high-level resistance. Fully resistant populations selected by passage through 8 micrograms/ml tetracycline either died or lost their resistance on further passage in antibiotic-free medium. Relatively large inocula were required to demonstrate resistance, and morphology of inclusions was altered at high tetracycline concentrations. The observed resistance may be a new characteristic of the organism or merely newly recognized. Isolates resistant to tetracycline were resistant to doxycycline, erythromycin, sulfamethoxazole, and clindamycin but sensitive to rifampin, ciprofloxacin, and ofloxacin. Thus, resistance to tetracycline, erythromycin, and clindamycin occurs in C. trachomatis and may be a factor in some treatment failures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230260     DOI: 10.1093/infdis/162.6.1309

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  L E Welsh; C A Gaydos; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Antimicrobial susceptibility and serotyping of Chlamydia trachomatis strains isolated before and after treatment with ciprofloxacin and doxycycline.

Authors:  A H van der Willigen; T van Rijsoord-Vos; J H Wagenvoort; W E Stamm; R J Suchland; E Stolz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

Review 4.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

5.  Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis.

Authors:  Anthony W Solomon; Zeena Mohammed; Patrick A Massae; John F Shao; Allen Foster; David C W Mabey; Rosanna W Peeling
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 6.  The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.

Authors:  P Horner
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

7.  In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys.

Authors:  P Butaye; R Ducatelle; P De Backer; H Vermeersch; J P Remon; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Tetracycline resistance in Chlamydia suis mediated by genomic islands inserted into the chlamydial inv-like gene.

Authors:  Jae Dugan; Daniel D Rockey; Loren Jones; Arthur A Andersen
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  The laboratory diagnosis of Chlamydia trachomatis infections.

Authors:  Max A Chernesky
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-01       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.